Serina Therapeutics (NYSEAMERICAN:SER) Shares Down 1% – What’s Next?

Serina Therapeutics, Inc. (NYSEAMERICAN:SER) fell 1% on Friday . The company traded as low as $1.98 and last traded at $2.07. 44,323 shares traded hands during mid-day trading, a decline of 4% from the average session volume of 46,056 shares. The stock had previously closed at $2.09.

Analyst Ratings Changes

Separately, BTIG Research initiated coverage on Serina Therapeutics in a research report on Wednesday, July 1st. They set a “buy” rating and a $8.00 price objective for the company. One research analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $8.00.

Serina Therapeutics Stock Performance

The firm has a market capitalization of $31.05 million, a PE ratio of -1.03 and a beta of 1.11. The company has a current ratio of 4.18, a quick ratio of 4.18 and a debt-to-equity ratio of 0.24. The company’s fifty day moving average price is $1.93.

Serina Therapeutics (NYSEAMERICAN:SER) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.58) earnings per share for the quarter.

About Serina Therapeutics

Serina Therapeutics, Inc, a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson’s disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson’s disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc was founded in 2006 and is based in Huntsville, Alabama.